Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Feb 15, 2020; 12(2): 182-194
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.182
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.182
Table 4 Dose modification, treatment delay and cessation, n (%)
| Variables | FOLFIRINOX (n = 86) | Gem + nabPTX (n = 81) | P value |
| Dose reduction | 76 (88.4) | 49 (60.5) | < 0.001 |
| At beginning | 43 (50) | 7 (8.6) | |
| Before 1st RE | 25 (29.1) | 12 (14.8) | |
| 1st RE-2nd RE | 5 (5.8) | 15 (18.5) | |
| After 2nd RE | 3 (3.5) | 15 (18.5) | |
| Delay of administration due to AE | 47 (54.7) | 51 (63.0) | 0.346 |
| Neurologic AE | 2 (2.4) | 14 (17.3) | |
| Hematologic AE | 30 (34.9) | 22 (27.2) | |
| Gastrointestinal AE | 3 (3.5) | 4 (4.9) | |
| General weakness | 8 (9.3) | 20 (24.7) | |
| Others | 6 (7.0) | 2 (2.5) | |
| Cessation of administration due to AE | 12 (14.0) | 17 (21.0) | 0.307 |
| Neurologic AE | 2 (2.4) | 3 (3.7) | |
| Hematologic AE | 1 (1.2) | 0 (0) | |
| Gastrointestinal AE | 1 (1.2) | 2 (2.5) | |
| General weakness | 8 (9.3) | 11 (13.6) | |
| Death | 0 (0) | 1 (1.2) |
- Citation: Cho IR, Kang H, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, An C, Park MS, Bang S. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World J Gastrointest Oncol 2020; 12(2): 182-194
- URL: https://www.wjgnet.com/1948-5204/full/v12/i2/182.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i2.182